Skip to main navigation menu Skip to main content Skip to site footer
×
Español (España) | English
Editorial
Home
Indexing
Original

Survival in patients with Triple Negative Breast Cancer Subtype: Institutional Experience

By
Christian Alexander Lema Guaraca ,
Christian Alexander Lema Guaraca

Clínica de Especialidades España. Cuenca, Ecuador

Search this author on:

PubMed | Google Scholar
Luis Xavier Illares Guncay ,
Luis Xavier Illares Guncay

Médico General en libre ejercicio profesional. Cuenca, Ecuador

Search this author on:

PubMed | Google Scholar
Andrés Sebastián Rodríguez Balarezo ,
Andrés Sebastián Rodríguez Balarezo

Servicio de Oncología. Hospital de Especialidades José Carrasco Arteaga, IEES. Cuenca, Ecuador

Search this author on:

PubMed | Google Scholar

Abstract

Background: Breast cancer with a triple-negative molecular profile is an aggressive disease with poor prognosis, regardless of stage. Since the mortality of these patients increases and their risk of relapse doubles or triples, overall and disease-free survival are typically short.
Methods: This was an observational, descriptive, and cross-sectional study. 44 clinical histories were analyzed in patients treated for triple-negative breast cancer in the Oncology Area of the Hospital “José Carrasco Arteaga” from 2014 to 2018, with a minimum follow-up time of 3 years. The variables included in the study were tumor stage, type of surgery, neoadjuvant chemotherapy, adjuvant chemotherapy, chemotherapeutic agents, mortality, disease relapse, overall survival, and disease-free survival. SPSS IMB version 21 was used to tabulate and analyze the collected data. The results are presented in graphics, single-entry, and double-entry tables.
Results: The study population included 44 patients, aged 30–93 years. The age between 50-69 years was the most frequently affected (54.6 %); 31.8% of the patients were in stage IIA at the time of diagnosis; the median disease-free survival it was 15.42 months (6-29); the frequency of relapses was 15.9% and mortality was 22.72%; the mean overall survival was 29.10 months (13-60); and there was a statistically significant relationship between disease relapse and locally advanced stage IIIA (p=0.004).
Conclusions: The prognosis of triple-negative breast carcinoma is poor, and because of its more aggressive behavior, it has a shorter disease-free interval and overall survival, presenting a greater risk of developing a poor response to treatment. Patients diagnosed at locally advanced stages of the disease have a higher risk of relapse.

How to Cite

1.
Lema Guaraca CA, Illares Guncay LX, Rodríguez Balarezo AS. Survival in patients with Triple Negative Breast Cancer Subtype: Institutional Experience. Salud, Ciencia y Tecnología [Internet]. 2023 Jul. 5 [cited 2024 Jul. 20];3:423. Available from: https://revista.saludcyt.ar/ojs/index.php/sct/article/view/423

The article is distributed under the Creative Commons Attribution 4.0 License. Unless otherwise stated, associated published material is distributed under the same licence.

Article metrics

Google scholar: See link

Metrics

Metrics Loading ...

The statements, opinions and data contained in the journal are solely those of the individual authors and contributors and not of the publisher and the editor(s). We stay neutral with regard to jurisdictional claims in published maps and institutional affiliations.